Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

aaeaaqaaaaaaaaiyaaaajgqxy2rmmzrlltrhmzktndzhns05mza3lwmwmjliywjmzdu5zg

Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare

October 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …
Appointment
teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
Appointment
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
Feature
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016 Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016 Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
News
msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016 Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
News
1280px-epi-pen_1

Mylan agrees $465m settlement over EpiPen misclassification

October 10, 2016 Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …
News
novartis_building

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016 Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
News

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
News
1280px-epi-pen_1

Mylan’s promised half-price EpiPen not available until year’s end

October 5, 2016 Research and Development, Sales and Marketing Mylan, epipen

Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …
News
jj_2johnson_and_johnson

Patients’ insulin pumps are revealed to be hackable by J&J

October 4, 2016 Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin

Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …
News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026